Privately held Tolmar, nearing completion on a manufacturing plant expansion, is now taking on some warehouse space to complement it.
Sun Pharma will start on the hard work now that it has closed on its $4 billion merger of Ranbaxy Laboratories. Managing Director Dilip Shanghvi has pledged that it will get all four of Ranbaxy's sideline plants into 100% compliance with FDA requirements.
India intends to establish 10 drug manufacturing clusters in the country and invest in infrastructure there like water, power and sewer treatment facilities that drugmakers can share in an effort to cut costs.
A Cypriot drugmaker with experience in Vietnam, a market that some Big Pharma players have taken an interest in, has decided on its own expansion there.
G&W Laboratories, a small generic drugmaker, recently broke onto the pharma scene publicly with two substantial deals in 10 months for plants and products. The first deal was last summer when it bought an Actavis plant, and this month it announced a deal to do the same with Teva Pharmaceutical Industries.
Nearly 250 workers at a closed Boehringer Ingelheim API facility in Virginia that had been told they might be able to hold on to their jobs have had their hopes dashed. The Chinese company that agreed to buy and expand the facility has decided to leave it closed until business improves.
Biotech Kite Pharma, which has become a force in cancer immunotherapy, has added some more manufacturing capabilities to the operations it has been beefing up.
AbbVie this week announced plans to expand in Puerto Rico, investing $30 million and creating up to 100 jobs on the island that has seen hits and misses in recent years from pharma manufacturers.
A Malaysian drugmaker has bulked up its manufacturing capacity as it faces drugmakers from other countries building plants there to grab a piece of a market that is seeing the kind of growth hard to come by in other parts of the world.
Actavis has completed its $66 billion buyout of Allergan, which has implications for the manufacturing networks of the two companies.